

HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Anticonvulsants

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:	
HPP Member Number:		Fax:	Phone:
Date of Birth:		Office Contact:	
Patient Primary Phone:		NPI:	PA PROMISe ID:
Address:		Address:	
City, State ZIP:		City, State ZIP:	
Line of Business: Medicaid CHIP		Specialty Pharmacy (if applicable):	
Drug Name:		Strength:	
Quantity:		Refills:	
Directions:			
Diagnosis Code:	Diagnosis:		
HPP's maximum approval time is 12 months but may be less depending on the drug.			

Please attach any pertinent medical history including labs and information for this member that may support approval.				
Please answer the following questions and sign.				
Q1. Is this a request for a gabapentinoid (e.g., gabapentin, p gabapentinoid (i.e., potential therapeutic duplication)?	regabalin) when there is a recent paid claim for another			
	□ No			
Q2. Is the patient being titrated to, or tapered from, another gabapentinoid?				
	□ No			
Q3. Has the prescriber provided supporting peer reviewed literature or national treatment guidelines to corroborate concomitant use of the medications being requested?				
☐ Yes	□ No			
Q4. Is this a request for clonazepam?				
	□ No			
Q5. Is the patient less than 21 years of age?				
	□ No			
Q6. Does the patient have any of the following diagnoses: A) seizure disorder, B) chemotherapy-induced nausea and vomiting, C) cerebral palsy, D) spastic disorder, E) dystonia?				
	□ No			
Q7. Is the patient receiving palliative care?				
	□ No			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Anticonvulsants

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
Q8. Does the patient have a concurrent prescription for a disorder?	buprenorphine agent indicated for the treatment of opioid use
☐ Yes	□ No
Q9. Are the prescriptions for the buprenorphine agent and	d the benzodiazepine written by the same prescriber?
☐ Yes	□ No
Q10. Are the prescribers of the buprenorphine agent and	the benzodiazepine aware of the other prescriptions?
☐ Yes	□ No
Q11. Does the patient have an acute need for therapy with	th a benzodiazepine?
☐ Yes	□ No
Q12. Is this a request for clonazepam when the patient has therapeutic duplication)?	as a recent claim for another benzodiazepine (i.e., potential
	□ No
Q13. Is the patient being titrated to, or tapered from, anot	her benzodiazepine?
☐ Yes	□ No
Q14. Has the prescriber provided supporting peer review concomitant use of the medications being requested?	ed literature or national treatment guidelines to corroborate
☐ Yes	□ No
Q15. Does the patient have a record of 2 or more paid cla	aims for any benzodiazepine in the past 30 days?
☐ Yes	□ No
Q16. Are the multiple benzodiazepine prescriptions consi standards of care, including support from peer-reviewed I use of the quantity of medication being prescribed?	stent with medically accepted prescribing practices and iterature or national treatment guidelines that corroborate the
☐ Yes	□ No
Q17. Are all of the prescriptions written by the same pres	criber?
☐ Yes	□ No
Q18. Are all of the prescribers aware of the other prescrip	otion(s)?
☐ Yes	□ No
Q19. Is there documentation that the prescriber, or the pr Prescription Drug Monitoring Program (PDMP) for the par	escriber's delegate, conducted a search of the Pennsylvania tient's controlled substance prescription history?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Anticonvulsants

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q20. Is this a request for a preferred anticonvu	ulsant?	
Yes	□ No	
Q21. Does the patient have a current history (v anticonvulsant?	within the past 90 days) of being prescribed the requested non-preferred	
Yes	□ No	
Q22. Does the patient have a documented history of therapeutic failure, intolerance of, or contraindication to the preferred anticonvulsants approved or medically accepted for the patient's diagnosis? [Note: Therapeutic failure of preferred anticonvulsants MUST include the generic equivalent when the generic equivalent is designated as preferred.]		
Yes	□ No	
Q23. Is the requested drug being prescribed for the treatment of a diagnosis that is indicated in the Food and Drug Administration (FDA) approved package labeling OR a medically accepted indication?		
Yes	□ No	
Q24. Is the patient prescribed a dose that is co labeling, nationally recognized compendia, or p	onsistent with Food and Drug Administration (FDA) approved package peer-reviewed medical literature?	
Yes	□ No	
Q25. Is the requested drug age-appropriate for package labeling, nationally recognized compe	or the patient according to Food and Drug Administration (FDA) approved endia, or peer-reviewed medical literature?	
Yes	□ No	
Q26. Additional Information:		

Prescriber Signature

Date

Updated for 2023

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document